✦ LIBER ✦

Pre-clinical studies of a novel anti-mitotic agent, amphethinile

✍ Scribed by McGown, AT; Ewen, C; Smith, DB; Fox, BW

Book ID: 109836055
Publisher: Nature Publishing Group
Year: 1988
Tongue: English
Weight: 579 KB
Volume: 57
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1988.32

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Anti-tumor activity of calcitriol: pre-c

Anti-tumor activity of calcitriol: pre-clinical and clinical studies

✍ Donald L. Trump; Pamela A. Hershberger; Ronald J. Bernardi; Sharmilla Ahmed; Jos 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 111 KB

47 CRx-026: discovery and clinical devel

47 CRx-026: discovery and clinical development of a syncretic anti-mitotic agent with significant anti-cancer activity

✍ P.J. Elliott; M.S. Lee; M. Keegan; Y. Zhang; M.J. Nichols; A.A. Borisy; C.T. Kei 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Metabolism and Pharmacokinetic Studies o

Metabolism and Pharmacokinetic Studies of SB-9000—A Novel Anti-HBV agent

✍ John Coughlin; Seetharamaiyer Padmanabhan; Radhakrishnan Iyer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

878 PRE-CLINICAL CHARACTERISATION OF A N

878 PRE-CLINICAL CHARACTERISATION OF A NOVEL DIRECT ACTING ANTIVIRAL AGENT WITH A NEW MODE OF ACTION

✍ N. Wilsher; S. Saalau-Bethell; A. Woodhead; A. Millemaggi; B. Graham; C. Hamlett 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Testing additivity of anticancer agents

Testing additivity of anticancer agents in pre-clinical studies: A PK/PD modelling approach

✍ M. Rocchetti; F. Del Bene; M. Germani; F. Fiorentini; I. Poggesi; E. Pesenti; P. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 769 KB

Pre-clinical development of the anti-tum

Pre-clinical development of the anti-tumour agent CB 7646, BIS N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol

✍ H.M. Coley; M. Jarman; N. Brooks; T. Kubota; P.M. Goddard; M. Jones; N. Lee; M.D 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 866 KB

Formulation difficulties prevented the otherwise promising clinical development of the anti-tumour agent trimelamol (TM; tris-[hydroxymethyl]trimethylmelamine]). A synthetic analogue programme resulted in the identification of CB 7646 @is N-@~ydroxymethyl]trimethylmelamine) as a compound with improv